Davis CS - Search Results

1

Rise and regional disparities in buprenorphine utilization in the United States.

Pashmineh Azar AR, Cruz-Mullane A, Podd JC, Lam WS, Kaleem SH, Lockard LB, Mandel MR, Chung DY, Simoyan OM, Davis CS, Nichols SD, McCall KL, Piper BJ. Pashmineh Azar AR, et al. Among authors: davis cs. Pharmacoepidemiol Drug Saf. 2020 Jun;29(6):708-715. doi: 10.1002/pds.4984. Epub 2020 Mar 16. Pharmacoepidemiol Drug Saf. 2020. PMID: 32173955

2

Opioid Prescribing Laws Are Not Associated with Short-term Declines in Prescription Opioid Distribution.

Davis CS, Piper BJ, Gertner AK, Rotter JS. Davis CS, et al. Pain Med. 2020 Mar 1;21(3):532-537. doi: 10.1093/pm/pnz159. Pain Med. 2020. PMID: 31365095 Free PMC article.

3

Laws limiting prescribing and dispensing of opioids in the United States, 1989-2019.

Davis CS, Lieberman AJ. Davis CS, et al. Addiction. 2021 Jul;116(7):1817-1827. doi: 10.1111/add.15359. Epub 2021 Jan 18. Addiction. 2021. PMID: 33245795 Review.

4

Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.

Stein BD, Saloner BK, Golan OK, Andraka-Christou B, Andrews CM, Dick AW, Davis CS, Sheng F, Gordon AJ. Stein BD, et al. Among authors: davis cs. JAMA Health Forum. 2023 May 5;4(5):e231102. doi: 10.1001/jamahealthforum.2023.1102. JAMA Health Forum. 2023. PMID: 37234015 Free PMC article.

5

Declining but Pronounced State-Level Disparities in Prescription Opioid Distribution in the United States.

Madera JD, Ruffino AE, Feliz A, McCall KL, Davis CS, Piper BJ. Madera JD, et al. Among authors: davis cs. Pharmacy (Basel). 2024 Jan 16;12(1):14. doi: 10.3390/pharmacy12010014. Pharmacy (Basel). 2024. PMID: 38251408 Free PMC article.

6

Legal changes to increase access to naloxone for opioid overdose reversal in the United States.

Davis CS, Carr D. Davis CS, et al. Drug Alcohol Depend. 2015 Dec 1;157:112-20. doi: 10.1016/j.drugalcdep.2015.10.013. Epub 2015 Oct 22. Drug Alcohol Depend. 2015. PMID: 26507172

7

Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid.

Gertner AK, Domino ME, Davis CS. Gertner AK, et al. Among authors: davis cs. Drug Alcohol Depend. 2018 Sep 1;190:37-41. doi: 10.1016/j.drugalcdep.2018.05.014. Epub 2018 Jun 22. Drug Alcohol Depend. 2018. PMID: 29966851

8

Letter to the Editor.

Davis CS, Carr DH. Davis CS, et al. J Law Med Ethics. 2018 Sep;46(3):811-812. doi: 10.1177/1073110518804248. J Law Med Ethics. 2018. PMID: 30336099 No abstract available.

9

The SUPPORT for Patients and Communities Act - What Will It Mean for the Opioid-Overdose Crisis?

Davis CS. Davis CS. N Engl J Med. 2019 Jan 3;380(1):3-5. doi: 10.1056/NEJMp1813961. Epub 2018 Nov 14. N Engl J Med. 2019. PMID: 30428274 Free article. No abstract available.

10

Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States.

Davis CS, Carr DH. Davis CS, et al. Int J Drug Policy. 2019 Nov;73:42-48. doi: 10.1016/j.drugpo.2019.07.006. Epub 2019 Jul 20. Int J Drug Policy. 2019. PMID: 31336293

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

357 results

Search Page